Rexahn

Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck
Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck
BioSpace
Rexahn
triple negative breast cancer
Merck
Keytruda
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
Flag link:
Rexahn's Human Data Confirms Anti-Cancer Advantage
Rexahn's Human Data Confirms Anti-Cancer Advantage
Yahoo
Rexahn
RX-3117
Supinoxin
cancer
Flag link:
Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off
Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off
Seeking Alpha
Rexahn
RX-3117
Eli Lilly
Gemzar
solid tumors
Flag link:
Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors
Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors
Pharmiweb
Supinoxin
Rexahn
Flag link:
Think Like a Brain Surgeon: Dr. Christopher James Offers Fresh Perspectives on Six Exciting Biotechs
Think Like a Brain Surgeon: Dr. Christopher James Offers Fresh Perspectives on Six Exciting Biotechs
IT Business Net
Opexa
Biocryst
Rexahn
Corcept Therapeutics
Ligand Pharmaceuticals
MannKind
Flag link:
Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff
Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff
Seeking Alpha
Taxotere
Rexahn
RX-21101
patents
patent cliff
Bristol-Myers Squibb
Roche
Sanofi
Flag link:
It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
TheStreet.com
biotech
Intercept Pharma
Rexahn
CorMedix
Neurocrine
Cell Therapeutics
Flag link:
3 Biotechs Getting Plenty Of Attention From Investors
3 Biotechs Getting Plenty Of Attention From Investors
Seeking Alpha
Depomed
Rexahn
Cambia
Zipsor
Gralise
Cangene
Emergent BioSolutions
Flag link:
Why Rexahn Pharmaceuticals (RNN) Is Up Today
Why Rexahn Pharmaceuticals (RNN) Is Up Today
TheStreet.com
Rexahn
Archexin
Supinoxin
RX-3117
Flag link:
Rexahn: A Turn Around Story For 2014
Rexahn: A Turn Around Story For 2014
Seeking Alpha
Rexahn
oncology
Flag link:
Rexahn's Recent Clinical Data Points To A New And Better Chemotherapy Pill
Rexahn's Recent Clinical Data Points To A New And Better Chemotherapy Pill
Seeking Alpha
Rexahn
chemotherapy
Amgen
Bristol-Myers Squibb
Merck
Novartis
Teva
RX-3117
Flag link:
Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble
Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble
Seeking Alpha
Teva
Rexahn
RX-3117
Flag link:
Teva-Rexahn Deal Terminated - Analyst Blog
Teva-Rexahn Deal Terminated - Analyst Blog
NASDAQ
Teva
Rexahn
RX-3117
Flag link:
Rexahn's CEO Uses A Business-Driven Cancer Model For Shareholder Value
Rexahn's CEO Uses A Business-Driven Cancer Model For Shareholder Value
Seeking Alpha
Rexahn
Merck
Novo Nordisk
Teva
Archexin
cancer
Flag link:
Rexahn awarded U.S. patent for novel anti-cancer compounds
Rexahn awarded U.S. patent for novel anti-cancer compounds
Yahoo/Fly on the Wall
patents
Rexahn
quinazoline
anti-tumor
Flag link:
Rexahn says to continue RX-3117 development with Teva
Rexahn says to continue RX-3117 development with Teva
The Fly on the Wall
Rexahn
RX-3117
Teva
RX-5902
Archexin
Flag link:
Rexahn Pharmaceuticals: Update On Cancer Drugs
Rexahn Pharmaceuticals: Update On Cancer Drugs
Seeking Alpha
Teva Pharmaceuticals
Rexahn
Archexin
RX-3117
RX-5902
RX-8243
cancer
akt protein inhibitor
Flag link:
You Should Have Seen These Biotech Failures Coming
You Should Have Seen These Biotech Failures Coming
Motley Fool
Oxigene
Rexahn
Flag link:
Rexahn Pharmaceuticals advances pancreatic cancer drug
Rexahn Pharmaceuticals advances pancreatic cancer drug
Bizjournals.com
Rexahn
pancreatic cancer
Flag link:

Pages